Skye Bioscience Faces Class Action for Misleading Statements; Investors May Claim Compensation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 27 2025
0mins
Source: Globenewswire
- Class Action Reminder: Rosen Law Firm alerts investors who purchased Skye Bioscience (NASDAQ: SKYE) securities between November 4, 2024, and October 3, 2025, that the deadline to apply as lead plaintiff is January 16, 2026, allowing for potential compensation without out-of-pocket costs.
- Allegations of Misleading Statements: The lawsuit claims that Skye made materially false and misleading statements regarding the effectiveness and commercial prospects of nimacimab during the class period, resulting in investor losses when the truth emerged.
- Legal Counsel Recommendations: Rosen Law Firm advises investors to select qualified counsel with a proven track record in securities class actions to ensure effective representation, steering clear of firms that merely act as intermediaries.
- Historical Performance: The firm has recovered over $438 million for investors in 2019 alone and achieved the largest securities class action settlement against a Chinese company in 2017, underscoring its strong capabilities in securities litigation.
Analyst Views on SKYE
Wall Street analysts forecast SKYE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SKYE is 9.80 USD with a low forecast of 2.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 0.780
Low
2.00
Averages
9.80
High
20.00
Current: 0.780
Low
2.00
Averages
9.80
High
20.00
About SKYE
Skye Bioscience, Inc. is a clinical-stage biotechnology company. The Company is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The Company is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The Company's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
